Tularemia Treatment in Neonates: Full-Term Infants ≤28 Days or Premature Infants at 37–44 Weeks Postmenstrual Age

Tularemia in the newborn period is managed differently from older children and adults. Age-specific boundaries define who falls into the neonatal category, and clinical status guides how treatment is initiated and sequenced.

Patient Population Neonates in this protocol are defined as full-term infants aged ≤28 days, or infants born premature who have reached 37–44 weeks postmenstrual age. These age thresholds determine which treatment approach applies.

Treatment Approach — Partial Overview First-line management calls for antimicrobial monotherapy; the specific agents, administration pathway, and guidance for ill-appearing neonates with relevant maternal exposure history are detailed in the full protocol. The regimen includes a provision for presumptive initiation in select clinical scenarios.

Instant Access to Structured Evidence-Based Regimens

References

For these recommendations, neonates are defined as full-term infants aged ≤28 days or infants born premature who have reached 37–44 weeks postmenstrual age.

Gentamicin and ciprofloxacin are first-line agents as monotherapy for treatment of tularemia in neonates.

This approach also can be used to transition neonates from IV to oral antimicrobials for treatment of tularemia once they have clinically improved.

For ill-appearing neonates born to mothers with untreated or inadequately treated tularemia, clinicians should initiate presumptive treatment with gentamicin while pursuing additional diagnostic workup.

View source ↗